pharma companies news from FierceHealthcare
NewsMed school docs still break conflict-of-interest rules
While some medical schools continue to get smarter when it comes to implementing conflict-of-interest policies, as FierceHealthcare reported last Friday, many physicians at several prominent schools Read more...
Surprising facts about pharma's best paid pill-pushing docs
When doctors discuss what a medication can do, it confers a veneer of respectability on the drug company's marketing. But a ProPublica investigation uncovered that fewer than half of the best paid Read more...
Studies raise questions about how much drug safety info should be released
Prescription scares have caused a number of sources, including the FDA, to release a lot more prescription safety information--but could it be too much information? Several recent studies have raised Read more...
ALSO NOTED: MN Gov. withdraws healthcare promise; Cancer patients take front line in early-stage trials; and much more...
> Minnesota Gov. Tim Pawlenty withdrew promised support for a bill designed to cut healthcare spending by nearly 20 percent by 2015, citing a lack of support from Republican House members. Read more...
ALSO NOTED: Consolidation in the medical tourism biz; LA county closing clinics; and much more...
> Consolidation is already happening in the medical tourism business: Greenwood Village, CO-based BridgeHealth International has agreed to buy New York-based Medical Tours International. Read more...
Merck agrees to pay$650M+ to settle suits
Merck has agreed to pay more than $650 million to settle two whistleblower suits, the U.S. Justice Department has announced. One of the suits claimed that the pharma paid providers to use its Read more...
Study:Many MDs won't see sales reps
A new study suggests that nearly one-fifth of office-based physicians refuse to see sales reps from the drug and device industry, and nearly 23 percent more won't see the reps unless they set an Read more...
VA removes Avandia from its formulary
VA dealt a body blow to type 2 diabetes drug Avandia this week, deciding that while it would continue to make the drug available to existing users, officials would no longer allow it to be prescribed Read more...
Avandia slammed by more studies
Two more studies have come out which raise further questions about the safety of diabetes drug Avandia. The first of the two studies, which were published in The Journal of the American Medical Read more...
Data providers challenge prescription-privacy laws
A group of large vendors that makes its living selling medical data to pharma companies is challenging state laws in Maine and Vermont that make physicians prescription-writing private. The Read more...
| Press ReleasesLexington, KY Market Provides Opportunities for Pharma SalesGovernor’s Veto of Proposed Health System Merger Means Business as Usual For Pharma, According to a Recent Market Overview Now Available from HealthLeaders-InterStudy NASHVILLE, Tenn.--(BUSINESS Read more >> PX’Therapeutics Licenses RIBOVAX’s SEBVI Technology for the Development and Manufacturing of Fully Human Monoclonal AntiboGRENOBLE, France--(BUSINESS WIRE)-- PX’Therapeutics SA (PX’T) and ribOvax Biotechnologies SA (Ribovax) have announced that they have entered into a licensing agreement to provide PX’T with access to Read more >> Taking The Pulse® Asia Explores the Professional Resource Mix and Digital Behaviors and Attitudes of Physicians in Japan, China,Manhattan Research's Second Version of its Asian Physician Research Complements the U.S. and European Studies to Give Pharma Companies a More Holistic View of the Global HCP MarketNEW YORK, July 27 Read more >> Thomson Reuters Creates The Outpartnering Registry, a Free Resource to Improve Drug Development PartneringPHILADELPHIA and LONDON, June 21 /PRNewswire/ -- Thomson Reuters announced today that it has launched The Outpartnering Registry, an innovative resource designed to change the way biotechnology, Read more >> |
